Stryker Corporation $SYK Shares Acquired by SouthState Corp

SouthState Corp increased its stake in Stryker Corporation (NYSE:SYK) by 2.5% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 19,615 shares of the medical technology company’s stock after buying an additional 482 shares during the quarter. SouthState Corp’s holdings in Stryker were worth $7,760,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of SYK. Brighton Jones LLC lifted its holdings in Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after purchasing an additional 609 shares during the period. Penserra Capital Management LLC lifted its holdings in Stryker by 125.8% in the first quarter. Penserra Capital Management LLC now owns 2,032 shares of the medical technology company’s stock worth $756,000 after purchasing an additional 1,132 shares during the period. Envestnet Asset Management Inc. raised its position in Stryker by 1.1% in the first quarter. Envestnet Asset Management Inc. now owns 632,180 shares of the medical technology company’s stock worth $235,329,000 after acquiring an additional 7,046 shares in the last quarter. TD Private Client Wealth LLC raised its position in Stryker by 5.3% in the first quarter. TD Private Client Wealth LLC now owns 5,429 shares of the medical technology company’s stock worth $2,021,000 after acquiring an additional 272 shares in the last quarter. Finally, U.S. Capital Wealth Advisors LLC raised its position in Stryker by 1.7% in the first quarter. U.S. Capital Wealth Advisors LLC now owns 3,633 shares of the medical technology company’s stock worth $1,352,000 after acquiring an additional 61 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Price Performance

Shares of SYK opened at $357.76 on Thursday. The company has a market capitalization of $136.82 billion, a price-to-earnings ratio of 47.39, a P/E/G ratio of 2.66 and a beta of 0.94. Stryker Corporation has a fifty-two week low of $329.16 and a fifty-two week high of $406.19. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The business’s 50-day moving average is $376.08 and its 200-day moving average is $381.07.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share for the quarter, beating analysts’ consensus estimates of $3.13 by $0.06. The company had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm’s quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities research analysts expect that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on SYK shares. Rothschild Redb upgraded shares of Stryker to a “hold” rating in a research report on Thursday, September 18th. Needham & Company LLC boosted their price target on shares of Stryker from $442.00 to $448.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. Sanford C. Bernstein reiterated an “outperform” rating on shares of Stryker in a research report on Monday. BTIG Research boosted their price target on shares of Stryker from $408.00 to $410.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Finally, Evercore ISI dropped their price target on shares of Stryker from $410.00 to $405.00 and set an “outperform” rating on the stock in a research report on Friday, October 31st. Fourteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, Stryker presently has an average rating of “Moderate Buy” and an average target price of $433.37.

Insider Buying and Selling at Stryker

In related news, insider Viju Menon sold 500 shares of the business’s stock in a transaction that occurred on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the sale, the insider owned 12,511 shares of the company’s stock, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 5.90% of the stock is owned by corporate insiders.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.